【cam loan】Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q'18 Performance
SAN FRANCISCO,cam loan CA / ACCESSWIRE / January 2, 2019 /
Jaguar Health, Inc. (
JAGX
) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that Company management will host a conference call on Monday, January 7, 2019 at 8 a.m. Eastern Time to discuss 4Q'18 performance.
Dial-In Instructions for Conference Call
When:
January 7, 2019 at 8 a.m. Eastern Time
Dial-in (US Toll Free):
800-289-0438
Dial-in (International):
323-794-2423
Conference ID number:
3695186
Live webcast on the investor relations section of Jaguar's website (
click here
)
Replay Instructions
Dial-in (US Toll Free):
844-512-2921
Dial-in (International):
412-317-6671
Conference ID number:
3695186
Replay of the webcast on the investor relations section of Jaguar's website (
click here
)
About Jaguar Health, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi
®
(crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
For more information about Jaguar, please visit
jaguar.health
. For more information about Napo, visit
napopharma.com
.
About Mytesi
®
Mytesi
®
(crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi
®
is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi
®
. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at
Mytesi.com
. Crofelemer, the active ingredient in Mytesi
®
, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal
Croton lechleri
tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Story continues
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar will host a conference call on January 7, 2019. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Peter Hodge
Jaguar Health, Inc.
Jaguar-JAGX
SOURCE:
Jaguar Health, Inc.
View comments
(责任编辑:Encyclopedia)
- US$4.75 - That's What Analysts Think Century Aluminum Company (NASDAQ:CENX) Is Worth After These Results
- U.S. State Department bans business with Cuban bank BFI
- China warns cities to cut reliance on property, developers' shares fall
- Click here to download this week's issue
- CANADA STOCKS-TSX plunges as coronavirus rout rages
- Tap These 5 Bargain Stocks With Enticing EV/EBITDA Ratios
- Robuxgenerator Inc Launches Free Robux Generator to Get Free Robux in 2022 without Verification
- Thousands fired after garment industry protest in Bangladesh
- U.S. State Department bans business with Cuban bank BFI
- Aptose to Hold Corporate Update Sunday, December 6th
- The iPhone upgrade test: Apple investors still in search of a reason to get really excited about buying stock
- Your guide to all the summer 2020 TV premiere dates
- BRIEF- Longino & Cardenal Prelim. FY Revenue Up 12.2 pct YoY
-
NEW YORK, NY / ACCESSWIRE / December 3, 2020 /Bernstein Liebhard, a nationally acclaimed investor ri ...[详细]
-
Why Just Eat plc (LON:JE.) Is A Financially Healthy Company
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies s ...[详细] -
BRIEF-Tianjin Teda Biomedical Engineering Co Says Sun Li Resigned As CEO
Feb 1 (Reuters) - Tianjin TEDA Biomedical Engineering Co Ltd :* SUN LI RESIGNED AS CEO* YANG JUNMIN ...[详细] -
Investors Are Undervaluing Fletcher Building Limited (NZSE:FBU) By 42.07%
I am going to run you through how I calculated the intrinsic value of Fletcher Building Limited (NZS ...[详细] -
StockBeat: Virus Derails Intu's Rescue Plan
By Geoff SmithInvesting.com - The coronavirus appears to have claimed its latest victim in U.K. shop ...[详细] -
Can Vixtel Technologies Holdings Limited (HKG:1782) Maintain Its Strong Returns?
While some investors are already well versed in financial metrics (hat tip), this article is for tho ...[详细] -
China's manufacturing activity shrinks again in February but at slower pace
By Yawen Chen and Ryan WooBEIJING (Reuters) - China's factory activity contracted for a third straig ...[详细] -
Building on a decade of successful child sex trafficking advocacy through the Protected Innocence Ch ...[详细]
-
NEW YORK, May 01, 2020 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action l ...[详细]
-
Evaluating New Times Energy Corporation Limited’s (HKG:166) Investments In Its Business
Want to help shape the future of investing tools? Participate in ashort research studyand receive a ...[详细]
IIOT-OXYS, Provides Business Update on COVID-19
Nexon founder to sell controlling stake in gaming co's holding firm - report
- Harvard and Yale Are No Match for the Bears
- Provident Financial: 4Q Earnings Snapshot
- DCB Holdings Limited (HKG:8040) Earns Among The Best Returns In Its Industry
- Should Aurea SA (EPA:AURE) Focus On Improving This Fundamental Metric?
- Capstar Financial Holdings, Inc. (NASDAQ:CSTR) Passed Our Checks, And It's About To Pay A US$0.05 Dividend
- European shares start 2019 shakily as China, EU figures deepen gloom
- Upcoming Deadline Reminder: The Schall Law Firm Encourages Investors in Marathon Digital Holdings, Inc. with Losses of $100,000 to Contact the Firm